343 related articles for article (PubMed ID: 30711575)
1. Repurposing host-based therapeutics to control coronavirus and influenza virus.
Li CC; Wang XJ; Wang HR
Drug Discov Today; 2019 Mar; 24(3):726-736. PubMed ID: 30711575
[TBL] [Abstract][Full Text] [Related]
2. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M
Front Immunol; 2019; 10():60. PubMed ID: 30761132
[TBL] [Abstract][Full Text] [Related]
3. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy.
Pizzorno A; Padey B; Terrier O; Rosa-Calatrava M
Front Immunol; 2019; 10():531. PubMed ID: 30941148
[TBL] [Abstract][Full Text] [Related]
4. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections.
Shen LW; Mao HJ; Wu YL; Tanaka Y; Zhang W
Biochimie; 2017 Nov; 142():1-10. PubMed ID: 28778717
[TBL] [Abstract][Full Text] [Related]
5. Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
McKimm-Breschkin JL; Fry AM
Antiviral Res; 2016 May; 129():21-38. PubMed ID: 26872862
[TBL] [Abstract][Full Text] [Related]
6. Coronavirus puts drug repurposing on the fast track.
Harrison C
Nat Biotechnol; 2020 Apr; 38(4):379-381. PubMed ID: 32205870
[No Abstract] [Full Text] [Related]
7. Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means.
Terrier O; Slama-Schwok A
Adv Exp Med Biol; 2021; 1322():195-218. PubMed ID: 34258742
[TBL] [Abstract][Full Text] [Related]
8. The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.
Schräder T; Dudek SE; Schreiber A; Ehrhardt C; Planz O; Ludwig S
Antiviral Res; 2018 Sep; 157():80-92. PubMed ID: 29990517
[TBL] [Abstract][Full Text] [Related]
9. Antiviral effects of inhibiting host gene expression.
Tripp RA; Mark Tompkins S
Curr Top Microbiol Immunol; 2015; 386():459-77. PubMed ID: 25007848
[TBL] [Abstract][Full Text] [Related]
10. [The recent advances in the host targets of anti-influenza drugs].
Ma LL; Jiang JD; Li YH
Yao Xue Xue Bao; 2014 Dec; 49(12):1631-8. PubMed ID: 25920190
[TBL] [Abstract][Full Text] [Related]
11. Nisoldipine Inhibits Influenza A Virus Infection by Interfering with Virus Internalization Process.
Huang Y; Li Y; Chen Z; Chen L; Liang J; Zhang C; Zhang Z; Yang J
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560742
[TBL] [Abstract][Full Text] [Related]
12. RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals.
Lesch M; Luckner M; Meyer M; Weege F; Gravenstein I; Raftery M; Sieben C; Martin-Sancho L; Imai-Matsushima A; Welke RW; Frise R; Barclay W; Schönrich G; Herrmann A; Meyer TF; Karlas A
PLoS Pathog; 2019 Mar; 15(3):e1007601. PubMed ID: 30883607
[TBL] [Abstract][Full Text] [Related]
13. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.
Mustafa S; Balkhy H; Gabere MN
J Infect Public Health; 2018; 11(1):9-17. PubMed ID: 28864360
[TBL] [Abstract][Full Text] [Related]
14. De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.
Wang C; Zhao L; Xia S; Zhang T; Cao R; Liang G; Li Y; Meng G; Wang W; Shi W; Zhong W; Jiang S; Liu K
J Med Chem; 2018 Oct; 61(19):8734-8745. PubMed ID: 30192544
[TBL] [Abstract][Full Text] [Related]
15. Assessing the potential of repurposing ion channel inhibitors to treat emerging viral diseases and the role of this host factor in virus replication.
Russell T; Gangotia D; Barry G
Biomed Pharmacother; 2022 Dec; 156():113850. PubMed ID: 36411658
[TBL] [Abstract][Full Text] [Related]
16. Porcine innate and adaptative immune responses to influenza and coronavirus infections.
Charley B; Riffault S; Van Reeth K
Ann N Y Acad Sci; 2006 Oct; 1081(1):130-6. PubMed ID: 17135502
[TBL] [Abstract][Full Text] [Related]
17. Screening methods for influenza antiviral drug discovery.
Atkins C; Evans CW; White EL; Noah JW
Expert Opin Drug Discov; 2012 May; 7(5):429-38. PubMed ID: 22435452
[TBL] [Abstract][Full Text] [Related]
18. Organotypic lung tissue culture as a preclinical model to study host- influenza A viral infection: A case for repurposing of nafamostat mesylate.
Saglam-Metiner P; Yildiz-Ozturk E; Tetik-Vardarli A; Cicek C; Goksel O; Goksel T; Tezcanli B; Yesil-Celiktas O
Tissue Cell; 2024 Apr; 87():102319. PubMed ID: 38359705
[TBL] [Abstract][Full Text] [Related]
19. Drug Repurposing: New Treatments for Zika Virus Infection?
Cheng F; Murray JL; Rubin DH
Trends Mol Med; 2016 Nov; 22(11):919-921. PubMed ID: 27692879
[TBL] [Abstract][Full Text] [Related]
20. The Mechanisms for Within-Host Influenza Virus Control Affect Model-Based Assessment and Prediction of Antiviral Treatment.
Cao P; McCaw JM
Viruses; 2017 Jul; 9(8):. PubMed ID: 28933757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
